Business UpdateJun 8, 2026, 04:17 PM
Century Therapeutics Presents Preclinical Data for Type 1 Diabetes Therapy
AI Summary
Century Therapeutics, Inc. announced the presentation of preclinical data for its investigational iPSC-derived islet replacement therapy, CNTY-813, at the American Diabetes Association (ADA) 2026 Scientific Sessions. The data highlighted durable glucose control, immune evasion capabilities of its Allo-Evasion™ 5.0 technology, and a successfully established Phase 1 clinical manufacturing process. The company remains on track for an IND submission in Q4 2026, with initial clinical data anticipated in 2H 2027, positioning CNTY-813 as a potential functional cure for Type 1 Diabetes.
Key Highlights
- Century Therapeutics presented preclinical data for its iPSC-derived cell therapy platform, CNTY-813, at the American Diabetes Association (ADA) 2026 Scientific Sessions.
- CNTY-813 demonstrated durable in-vivo glucose control for over eight months in preclinical models.
- The therapy's Allo-Evasion™ 5.0 technology showed immune evasion capabilities, maintaining insulin secretion and normoglycemia without immunosuppression in a humanized mouse model.
- Phase 1 clinical manufacturing process established, demonstrating consistent endocrine purity and optimal islet cell content.
- An Investigational New Drug (IND) submission for CNTY-813 is on track for the fourth quarter of 2026, with initial clinical data expected in the second half of 2027.
Price Impact
More from IPSC